Infrared spectroscopy: A new diagnostic tool in Alzheimer disease

Neuroscience Letters

Volumn 420, Issue 1, 2007, Pages 29-33

  Griebe, Martin ^a   Daffertshofer, Michael ^a   Stroick, Mark ^a   Syren, Magdalena ^b   Ahmad Nejad, Parviz ^a   Neumaier, Michael ^a   Backhaus, Juergen ^c   Hennerici, Michael G ^a   Fatar, Marc ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c MANNHEIM UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Alzheimer disease; Artificial neural networks; Biomarkers; Cerebrospinal fluid; Infrared spectroscopy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; SPECTROPHOTOMETRY, INFRARED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TAU PROTEINS; YOUNG ADULT;

EID: 34248670691     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.03.075     Document Type: Article

References (24)

1. Agatonovic-Kustrin S., and Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J. Pharm. Biomed. Anal. 22 (2000) 717-727
2. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
3. Argov S., Ramesh J., Salman A., Sinelnikov I., Goldstein J., Guterman H., and Mordechai S. Diagnostic potential of Fourier-transform infrared microspectroscopy and advanced computational methods in colon cancer patients. J. Biomed. Opt. 7 (2002) 248-254
4. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., and Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1 (1991) 103-116
5. J. Backhaus, R. Mischler, D. Boecker, Method of analyzing clinically relevant liquids and suspensions, Boehringer Mannheim GmbH, 307416 [US-Patent No. 5734587], 1998, Germany, 19-9-1994.
6. Bayer T.A., Wirths O., Majtenyi K., Hartmann T., Multhaup G., Beyreuther K., and Czech C. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11 (2001) 1-11
7. Berg L., McKeel Jr. D.W., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., and Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55 (1998) 326-335
8. Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., and Perl D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52 (1995) 81-88
9. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2 (2003) 605-613
10. Boydston-White S., Gopen T., Houser S., Bargonetti J., and Diem M. Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. Biospectroscopy 5 (1999) 219-227
11. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel Jr. D.W., Farlow M., Weitlauf S.L., Quinn J., Kaye J., Knopman D., Arai H., Doody R.S., DeCarli C., Leight S., Lee V.M., and Trojanowski J.Q. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol. 60 (2003) 1696-1702
12. Klatka L.A., Schiffer R.B., Powers J.M., and Kazee A.M. Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study. Arch. Neurol. 53 (1996) 35-42
13. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., Small G.W., Miller B., and Stevens J.C. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1143-1153
14. Lasch P., Haensch W., Lewis E.N., Kidder L.H., and Naumann D. Characterization of colorectal adenocarcinoma sections by spatially resolved FT-IR microspectroscopy. App. Spectrosc. 56 (2002) 1-9
15. Lasch P., Schmitt J., Beekes M., Udelhoven T., Eiden M., Fabian H., Petrich W., and Naumann D. Antemortem identification of bovine spongiform encephalopathy from serum using infrared spectroscopy. Anal. Chem. 75 (2003) 6673-6678
16. Maddalena A., Papassotiropoulos A., Muller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., and Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch. Neurol. 60 (2003) 1202-1206
17. Morris J.C. Dementia update 2003. Alzheimer Dis. Assoc. Disord. 17 (2003) 245-258
18. Petrich W. Mid-infrared and Raman spectroscopy for medical diagnostics. Appl. Spectrosc. Rev. 36 (2001) 181-237
19. Petrich W., Dolenko B., Fruh J., Ganz M., Greger H., Jacob S., Keller F., Nikulin A.E., Otto M., Quarder O., Somorjai R.L., Staib A., Warner G., and Wielinger H. Disease pattern recognition in infrared spectra of human sera with diabetes mellitus as an example. Appl. Opt. 39 (2000) 3372-3379
20. Pizzi N., Choo L.P., Mansfield J., Jackson M., Halliday W.C., Mantsch H.H., and Somorjai R.L. Neural network classification of infrared spectra of control and Alzheimer's diseased tissue. Artif. Intell. Med. 7 (1995) 67-79
21. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., and Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 118 (2003) 140-146
22. Selkoe D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110 (2002) 1375-1381
23. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
24. W.W. Wallesch, H. Foerstl, K. Herholz, C. Lang, K. Schmidtke. Leitlinien der Deutschen Gesellschaft für Neurologie: Diagnose und Therapie der Alzheimer-Demenz (AD) und der Demenz mit Lewy-Körperchen (DLB). http://www.dgn.org. 2002.